4 news items
Bristol Myers Updates Action Date for Subcutaneous Opdivo
ALXO
BMY
LGND
23 May 24
and demonstrate non-inferior pharmacokinetics, efficacy and consistent safety vis-a-vis its intravenous formulation (IV). The subcutaneous formulation has
Ligand Reports First Quarter 2024 Financial Results
AMGN
CASI
JAZZ
7 May 24
12 weeks of treatment and affirmed VK2809's potent effect on liver fat, along with its favorable tolerability and safety profile. Viking plans
Ligand and Agenus Enter Into $100 Million Royalty Financing Agreement
AGEN
LGND
7 May 24
(including validation of mechanism of action), potency, durability, and safety profile (including the absence of specific toxicities) of the Company's
Ligand Pharmaceuticals Announces New Topiramate Injection Data Presented at 9th London-Innsbruck Colloquium on Status Epilepticus and Acute Seizures Conference
LGND
8 Apr 24
of topiramate was compared to a dose of oral topiramate to assess safety and the dose of the IV topiramate needed to replicate the plasma concentrations
- Prev
- 1
- Next